Dr. Lawrence Baizer | Large-Scale Vision | Best Researcher Award
Doctorate at National Institutes of Health, United States
Profiles
Early Academic Pursuits
Dr. Lawrence Baizer embarked on his academic journey with a strong foundation in neurobiology and behavior, earning his B.A. from Cornell University in 1975. He then pursued his Ph.D. in Pharmacology at the University of Colorado School of Medicine, where he worked under the mentorship of Dr. Norman Weiner. His early research laid the groundwork for his future contributions to molecular mechanisms of neurodevelopment.
Professional Endeavors
With a career spanning multiple prestigious institutions, Dr. Baizer has made significant contributions to both basic and clinical research. His tenure at Massachusetts General Hospital-Harvard Medical School as a postdoctoral fellow led to pioneering discoveries in neurodevelopment. He later advanced to roles at Oregon Health Sciences University, where he established and directed research laboratories, mentored graduate students, and contributed to pharmacological education. His career trajectory further extended into clinical research, government funding administration, and scientific review at the National Institutes of Health (NIH).
Contributions and Research Focus
Dr. Baizer’s research portfolio encompasses a broad range of scientific disciplines, including neurodevelopment, pharmacology, molecular biology, immunology, oncology, and clinical research. His work at the National Cancer Institute (NCI) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) facilitated critical advancements in clinical trials, alcohol-related neurodevelopmental studies, and biomarker research. His current role at the National Center for Sleep Disorders Research involves overseeing NIH-funded projects on sleep and circadian rhythms, a field crucial to understanding cognitive and physiological health.
Impact and Influence
Throughout his career, Dr. Baizer has played a pivotal role in shaping research initiatives and fostering interdisciplinary collaborations. He has coordinated major NIH steering committees, reviewed and managed extensive grant portfolios, and influenced national research priorities in oncology, neurology, and sleep disorders. His contributions to RECOVER-related activities and clinical trial development for post-acute sequelae of COVID-19 (PASC) highlight his ongoing impact in translational science.
Academic Contributions and Citations
As a prolific researcher, Dr. Baizer has authored over 20 publications, including groundbreaking studies in neurodevelopment and neuropathology. He has contributed to clinical trial reviews, funding initiatives, and treatment recommendations, notably in hematologic malignancies and multiple myeloma. His work has been widely cited, reflecting the significance of his research in advancing medical knowledge.
Technical Expertise
Dr. Baizer’s expertise spans diverse scientific domains, including pharmacokinetics, genetics, immunology, and clinical research methodologies. His experience in grant administration, peer review processes, and translational research initiatives has made him a valuable asset in scientific funding and policy development.
Teaching and Mentorship
Beyond research, Dr. Baizer has made lasting contributions to education and mentorship. He has taught graduate-level courses in neurobiology and molecular genetics, mentored doctoral candidates, and organized international neuroscience conferences. His commitment to fostering the next generation of scientists is evident in his advisory roles and committee memberships.
Legacy and Future Contributions
Dr. Baizer’s extensive career reflects a dedication to advancing scientific inquiry, bridging clinical and basic research, and shaping the future of medical science. His leadership in grant funding, clinical trials, and policy-making continues to impact the global scientific community. As he remains actively involved in NIH initiatives and collaborative research efforts, his contributions will undoubtedly influence the trajectory of medical research for years to come.
Publications
Therapeutic trials for long COVID-19: a call to action from the interventions taskforce of the RECOVER initiative
- Authors: Hector Bonilla, Michael J Peluso, Kathleen Rodgers, Judith A Aberg, Thomas F Patterson, Robert Tamburro, Lawrence Baizer, Jason D Goldman, Nadine Rouphael, Amelia Deitchman, Jeffrey Fine, Paul Fontelo, Arthur Y Kim, Gwendolyn Shaw, Jeran Stratford, Patricia Ceger, Maged M Costantine, Liza Fisher, Lisa O’Brien, Christine Maughan, John G Quigley, Vilma Gabbay, Sindhu Mohandas, David Williams, Grace A McComsey
- Journal: Frontiers in immunology
- Year: 2023
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
- Authors: Shaji Kumar, Lawrence Baizer, Natalie S Callander, Sergio A Giralt, Jens Hillengass, Boris Freidlin, Antje Hoering, Paul G Richardson, Elena I Schwartz, Anthony Reiman, Suzanne Lentzsch, Philip L McCarthy, Sundar Jagannath, Andrew J Yee, Richard F Little, Noopur S Raje
- Journal: Blood cancer journal
- Year: 2022
Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0
- Authors: Sara M Tolaney, Elizabeth Garrett-Mayer, Julia White, Victoria S Blinder, Jared C Foster, Laleh Amiri-Kordestani, E Shelley Hwang, Judith M Bliss, Eileen Rakovitch, Jane Perlmutter, Patricia A Spears, Elizabeth Frank, Nadine M Tung, Anthony D Elias, David Cameron, Neelima Denduluri, Ana F Best, Angelo DiLeo, Lawrence Baizer, Lynn Pearson Butler, Elena Schwartz, Eric P Winer, Larissa A Korde
- Journal: Journal of clinical oncology
- Year: 2021
Hodgkin lymphoma: current status and clinical trial recommendations
- Authors: Catherine S Diefenbach, Joseph M Connors, Jonathan W Friedberg, John P Leonard, Brad S Kahl, Richard F Little, Lawrence Baizer, Andrew M Evens, Richard T Hoppe, Kara M Kelly, Daniel O Persky, Anas Younes, Lale Kostakaglu, Nancy L Bartlett
- Journal: JNCI: Journal of the National Cancer Institute
- Year: 2017
Beyond RCHOP: a blueprint for diffuse large B cell lymphoma research
- Authors: Grzegorz S Nowakowski, Kristie A Blum, Brad S Kahl, Jonathan W Friedberg, Lawrence Baizer, Richard F Little, David G Maloney, Laurie H Sehn, Michael E Williams, Wyndham H Wilson, John P Leonard, Sonali M Smith
- Journal: JNCI: Journal of the National Cancer Institute
- Year: 2016